Viewing Study NCT01633957


Ignite Creation Date: 2025-12-24 @ 6:51 PM
Ignite Modification Date: 2025-12-29 @ 10:17 AM
Study NCT ID: NCT01633957
Status: UNKNOWN
Last Update Posted: 2016-07-25
First Post: 2012-06-20
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Trial of Genotype-based Warfarin Initiation in Patients With Mechanical Prosthetic Heart Valve
Sponsor: Xi Zhang
Organization:

Study Overview

Official Title: Academic Leader,Head of Cardiac Surgery,Principal Investigator, Clinical Professor
Status: UNKNOWN
Status Verified Date: 2016-07
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: SYSU-WARFA
Brief Summary: Until very recently, warfarin is still the best drug of choice for long-term anticoagulation for patients with mechanical prosthetic heart valve. However, the complication of warfarin account for 75 percent of the whole complication after the mechanical prosthetic heart valve replacement.

Interindividual variation in warfarin dose is mediated by multiple factors.Advanced models using combinations of clinical attributes and genetic factors(CYP2C9, VKORC1, and CYP4F2) explain 50-75% of variability in warfarin dose requirements.These warfarin dosing models have the potential to improve patient safety by reducing or eliminating serious adverse events. The investigators conducted a prospective, randomized, blinded, two arm trial to test this hypothesis.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: